Koschinsky ML - Search Results

1

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Wilson DP, et al. Among authors: koschinsky ml. J Clin Lipidol. 2022 Sep-Oct;16(5):e77-e95. doi: 10.1016/j.jacl.2022.08.007. Epub 2022 Aug 26. J Clin Lipidol. 2022. PMID: 36068139

2

Lipoprotein(a): more interesting than ever after 50 years.

Dubé JB, Boffa MB, Hegele RA, Koschinsky ML. Dubé JB, et al. Among authors: koschinsky ml. Curr Opin Lipidol. 2012 Apr;23(2):133-40. doi: 10.1097/MOL.0b013e32835111d8. Curr Opin Lipidol. 2012. PMID: 22327610 Review.

3

The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?

Boffa MB, Koschinsky ML. Boffa MB, et al. Among authors: koschinsky ml. Curr Opin Lipidol. 2018 Jun;29(3):259-267. doi: 10.1097/MOL.0000000000000499. Curr Opin Lipidol. 2018. PMID: 29528858 Review.

4

Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.

Boffa MB, Stranges S, Klar N, Moriarty PM, Watts GF, Koschinsky ML. Boffa MB, et al. Among authors: koschinsky ml. J Clin Lipidol. 2018 Nov-Dec;12(6):1358-1366. doi: 10.1016/j.jacl.2018.08.012. Epub 2018 Sep 11. J Clin Lipidol. 2018. PMID: 30316749 Review.

5

JCL roundtable-Lipoprotein(a): The emerging risk factor.

Marcovina SM, Moriarty PM, Koschinsky ML, Guyton JR. Marcovina SM, et al. Among authors: koschinsky ml. J Clin Lipidol. 2018 Nov-Dec;12(6):1335-1345. doi: 10.1016/j.jacl.2018.11.003. J Clin Lipidol. 2018. PMID: 30527801

6

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Wilson DP, et al. Among authors: koschinsky ml. J Clin Lipidol. 2019 May-Jun;13(3):374-392. doi: 10.1016/j.jacl.2019.04.010. Epub 2019 May 17. J Clin Lipidol. 2019. PMID: 31147269

7

Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?

Boffa MB, Koschinsky ML. Boffa MB, et al. Among authors: koschinsky ml. Curr Opin Lipidol. 2019 Dec;30(6):428-437. doi: 10.1097/MOL.0000000000000641. Curr Opin Lipidol. 2019. PMID: 31577611 Review.

8

Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a).

Wilson DP, Koschinsky ML, Moriarty PM. Wilson DP, et al. Among authors: koschinsky ml. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):159-173. doi: 10.1097/MED.0000000000000624. Curr Opin Endocrinol Diabetes Obes. 2021. PMID: 33534258 Review.

9

Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know.

Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos RD, Shapiro MD, Saseen JJ. Virani SS, et al. Among authors: koschinsky ml. Prog Cardiovasc Dis. 2022 Jul-Aug;73:32-40. doi: 10.1016/j.pcad.2022.01.002. Epub 2022 Jan 19. Prog Cardiovasc Dis. 2022. PMID: 35063437 Free article. Review.

10

Understanding the ins and outs of lipoprotein (a) metabolism.

Boffa MB, Koschinsky ML. Boffa MB, et al. Among authors: koschinsky ml. Curr Opin Lipidol. 2022 Jun 1;33(3):185-192. doi: 10.1097/MOL.0000000000000823. Curr Opin Lipidol. 2022. PMID: 35695615 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

176 results

Search Page